Table Of Content

Subject Index A regulation of glucose metabolism, 395 C3d receptor, insulinoma cells, 809 See also Islet amyloid polypeptide Ca?+ Acanthosis nigricans, 548 1,5-anhydroglucitol, screening criterion, cytosolic, dioctanoylglycerol effects, Adipocytes 52 21 diabetes effects on phosphotyrosine Animal models. See Baboons; Dogs; effect of diabetes, 1560 and phosphoserine phosphatase, Mice; Rats phosphorylation of islet secretory 1620 Antihyperglycemic drugs, biguanide, granules, 1063 G, protein, impaired coupling, 88 zinc effect, 612 transport, effects of IPs, spermine, and in situ pathway metabolism, 1517 Apolipoprotein Mg?*, 323 Adipose tissue (a), insulin- dependent diabetes Calcitonin gene-related peptide brown, New Zealand obese mice, mellitus, microalbuminuria, 787 effect on rat islet amyloid dolypeptide, 1480 B gene, signal peptide-length 948 metabolism, insulin deprivation effects, variation, 1539 regulation of glucose metabolism. 395 666 E, Mexican Americans, 334 Calcitriol stimulation by insulin, 1134 a-Adrenergic receptor blockade effects, Ascorbic acid, collagen and Capillarization, fatty acid 1652 proteoglycan production, 371 supplementation, 532 Age, determinant of glucose tolerance, Asp 57, absence of, genetic Carbohydrate metabolism, lipid effects, 44 susceptibility to insulin- dependent 686 Aging diabetes mellitus, 1640 Carboxymethyllysine levels, aging, 190 carboxymethyllysine levels, 190 Atherosclerosis, nonenzymatic Cataracts development, glycosylation, collagen, X-ray diffraction, 391 glycosylated high-density 1010 Aggression, tryptophan effects, 1598 lipoproteins, 377 a-Cell, epinephrine effects, 1194 Albuminuria, aminoguanidine effects, ATP-sensitive K* channel, linogliride B-Cell 1328 effects, 885 adhesion molecules, 1382 Aldose reductase Atrial natriuretic peptide, nephropathy, desensitization to glucose, 486 activity and sorbitol accumulation in 893 destruction erythrocytes, 1233 Autoimmune thyroid disease, islet cell macrophage destruction, 1586 inhibitor antibodies, 319 prevention of by cyclophosphamide, endothelial cell dysjunction, 1090 Autonomic nervous system 1203 extracellular matrix changes, 1049 effect on glucagon secretion, 1107 -specific antigenic changes, 269 glomerular filtration rate, 527 familial, 1611 T lymphocytes role, 1210 peripheral neuropathy, 129 Axonal transport, 1114 dysfunction, chronic undernutrition, retinal pigment epithelial cells, 1335 1404 insulin and statil effects on expression, epinephrine effects, 1194 1391 function Alginate- polylysine- alginate B interleukin 1B effects, 290 microencapsulation, insulin release, phospholipase role, 1565 37 Baboons protease effects, 290 Alloxan, effects on H2O. generation and B-cell mass and insulin content, 673 GABA, 1365 DNA fragmentation, 1141 streptozocin-induced diabetes, galanin effects affected by G proteins, pulsatile insulin delivery, 349 Amino acids Basement membranes 1170 availéuity, insulinlike growth factor |, ionic channels, 1069 high glucose, 102 95 mass, pancreatic insulin content, 673 thickening, increased gene effect on muscle protein synthesis, 499 non-insulin- dependent diabetes expression, 605 5-Amino-4 -imidazolecarboxamide (AICA) mellitus, 166 riboside inhibition of Blacks, genetic susceptibility to NIT-1, 842 insulin- dependent diabetes mellitus. gluconeogenesis, 1259 pancreatic, heat shock protein 70 748 yy-Aminobutyric acid (GABA), 1365 protection, 1418 Aminoguanidine, effects on albuminuria Bladder, streptozocin receptor pulsatile insulin secretion, 1453 mesangial expansion and tissue Book rergeuvliaetwi,o n,a ni1m1a5l0 models, 1739 Children fluorescence, 1328 insulin-dependent diabetes mellitus Bronchial reactivity, 1100 Amylin decreased growth velocity, 211 decrease of stimulated release hypoglycemia, 358 precedes insulin release offspring risk decreases with impairment, 1615 increased maternal age at glucose level effect on secretion, 1005 Cc pregnancy, 1 insulin resistance through glycogen C-peptide, concentration level in Cholecystokinin-mediated synthesis, 568 Hispanic Americans, 509 phosphatidylinositol hydrolysis, 1282 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223—1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 Subject Index A regulation of glucose metabolism, 395 C3d receptor, insulinoma cells, 809 See also Islet amyloid polypeptide Ca?+ Acanthosis nigricans, 548 1,5-anhydroglucitol, screening criterion, cytosolic, dioctanoylglycerol effects, Adipocytes 52 21 diabetes effects on phosphotyrosine Animal models. See Baboons; Dogs; effect of diabetes, 1560 and phosphoserine phosphatase, Mice; Rats phosphorylation of islet secretory 1620 Antihyperglycemic drugs, biguanide, granules, 1063 G, protein, impaired coupling, 88 zinc effect, 612 transport, effects of IPs, spermine, and in situ pathway metabolism, 1517 Apolipoprotein Mg?*, 323 Adipose tissue (a), insulin- dependent diabetes Calcitonin gene-related peptide brown, New Zealand obese mice, mellitus, microalbuminuria, 787 effect on rat islet amyloid dolypeptide, 1480 B gene, signal peptide-length 948 metabolism, insulin deprivation effects, variation, 1539 regulation of glucose metabolism. 395 666 E, Mexican Americans, 334 Calcitriol stimulation by insulin, 1134 a-Adrenergic receptor blockade effects, Ascorbic acid, collagen and Capillarization, fatty acid 1652 proteoglycan production, 371 supplementation, 532 Age, determinant of glucose tolerance, Asp 57, absence of, genetic Carbohydrate metabolism, lipid effects, 44 susceptibility to insulin- dependent 686 Aging diabetes mellitus, 1640 Carboxymethyllysine levels, aging, 190 carboxymethyllysine levels, 190 Atherosclerosis, nonenzymatic Cataracts development, glycosylation, collagen, X-ray diffraction, 391 glycosylated high-density 1010 Aggression, tryptophan effects, 1598 lipoproteins, 377 a-Cell, epinephrine effects, 1194 Albuminuria, aminoguanidine effects, ATP-sensitive K* channel, linogliride B-Cell 1328 effects, 885 adhesion molecules, 1382 Aldose reductase Atrial natriuretic peptide, nephropathy, desensitization to glucose, 486 activity and sorbitol accumulation in 893 destruction erythrocytes, 1233 Autoimmune thyroid disease, islet cell macrophage destruction, 1586 inhibitor antibodies, 319 prevention of by cyclophosphamide, endothelial cell dysjunction, 1090 Autonomic nervous system 1203 extracellular matrix changes, 1049 effect on glucagon secretion, 1107 -specific antigenic changes, 269 glomerular filtration rate, 527 familial, 1611 T lymphocytes role, 1210 peripheral neuropathy, 129 Axonal transport, 1114 dysfunction, chronic undernutrition, retinal pigment epithelial cells, 1335 1404 insulin and statil effects on expression, epinephrine effects, 1194 1391 function Alginate- polylysine- alginate B interleukin 1B effects, 290 microencapsulation, insulin release, phospholipase role, 1565 37 Baboons protease effects, 290 Alloxan, effects on H2O. generation and B-cell mass and insulin content, 673 GABA, 1365 DNA fragmentation, 1141 streptozocin-induced diabetes, galanin effects affected by G proteins, pulsatile insulin delivery, 349 Amino acids Basement membranes 1170 availéuity, insulinlike growth factor |, ionic channels, 1069 high glucose, 102 95 mass, pancreatic insulin content, 673 thickening, increased gene effect on muscle protein synthesis, 499 non-insulin- dependent diabetes expression, 605 5-Amino-4 -imidazolecarboxamide (AICA) mellitus, 166 riboside inhibition of Blacks, genetic susceptibility to NIT-1, 842 insulin- dependent diabetes mellitus. gluconeogenesis, 1259 pancreatic, heat shock protein 70 748 yy-Aminobutyric acid (GABA), 1365 protection, 1418 Aminoguanidine, effects on albuminuria Bladder, streptozocin receptor pulsatile insulin secretion, 1453 mesangial expansion and tissue Book rergeuvliaetwi,o n,a ni1m1a5l0 models, 1739 Children fluorescence, 1328 insulin-dependent diabetes mellitus Bronchial reactivity, 1100 Amylin decreased growth velocity, 211 decrease of stimulated release hypoglycemia, 358 precedes insulin release offspring risk decreases with impairment, 1615 increased maternal age at glucose level effect on secretion, 1005 Cc pregnancy, 1 insulin resistance through glycogen C-peptide, concentration level in Cholecystokinin-mediated synthesis, 568 Hispanic Americans, 509 phosphatidylinositol hydrolysis, 1282 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223—1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 Choiesterogenesis, 1630 Dopamine turnover, insulin withdrawal, insulin action, 521 Clonidine, diuretic and natriuretic effects, 217 insulin release, 1 338 GABA, 1365 CoA. See Coenzyme A Galanin, G protein effects, 1170 Coenzyme A, coupling factors, 327 Gene Cognitive function, insulin- dependent expression diabetes mellitus, 952 basement membrane thickening, Collagen Endocrine function deterioration, rat islet 605 aging, X-ray diffraction, 391 transplantation, 134 PEPCK inhibition by oxidative stress, 405 Endosomes, insulin degradation, 436 pulsatile/continuous insulin, 990 production, ascorbic acid, 371 Endothelial cells transcription, high glucose, 102 Congenital malformations in mouse aldose reductase inhibitor, 1090 Genetic susceptibility embryo, 1245 human, basement membranes, 102 HLA-DQ af heterodimer, 759 Cortisol, physiological increase and in vivo study, 653 HLA-DQA1, blacks, 748 lipolysis stimulation, 1228 interaction with leukocytes, 1267 HLA-DQB1 Coupling factors, coenzyme A, 327 Epinephrine effects on a- and B-cells, blacks, 748 Cyclophosphamide, prevention of 1194 Finland, 1640 spontaneous diabetes in mice, 1203 Epithelium, pancreatic ductal, islet HLA-DR3 haplotype, 478 Cyclosporin cytodifferentiation, 1041 HLA-DR4 haplotypes, 478, 709 effect in islet transplantation, 931 Epstein-Barr virus, insulinoma cells, 809 Genetics remission phase of insulin- dependent Erythrocytes conginita! malformations in mouse diabetes mellitus, 598 aldose reductase activity and sorbitol embryo, 1245 accumulation, 1233 defects in glycosaminoglycan phospholipids, decreased regulation, 764 incorporation of long-chain fatty insulin resistance, 28, 548 acids, 1645 insulin-responsive glucose transporter D spectrin oxidation, 701 gene, molecular scanning, 1712 vitamin E reduced, effect on lipofuscin Glomerular filtration rate Dehydroepiandosterone, insulin products, 1241 aldose reductase inhibition, 527 resistance, 693 Ethanol, effect on hepatic glucose myo-inositol effects, 465 Dendritic cells production, 1319 polyol- pathway inhibition effects, 465 potency and graft survival, 1719 Etomoxir, effect on free fatty acids and Glucagon transplantation rejection, 754 insulin action, 783 effect on ouabain-sensitive Depression, tryptophan effects, 1598 Exercise Na*-K*-ATPase, 1603 Dexamethasone insulin release, 401 glycogen catabolism, 263 effects on insulin receptors, 58 muscle, glucose transporter, 275 -like peptide | in islets of Langerhans, insulin action, 181 1292 Diacylglycerol secretion increased by autonomic content in thoracic aorta, 820 nervous system, 1107 insulin stimulation, 1707 Glucohydrolase inhibitor, 825 Diabetic foot. See Feet F Gluconeogenesis inhibition Diaminoguanidine, 1079 Familial diabetes, 831, 1024, 1611 by AICA riboside, 1259 Diet Fatty acids by ethanol, 1319 fatty acid supplementation, 532 composition in thoracic aorta, 820 Glucoreceptors, hepatic, hypoglycemia, high-fat decreased incorporation into 55 glucose transporter, 275 erythrocyte phospholipids, 1645 Glucose insulin resistance, 280, 1397 w-3, insulin resistance, 280 arterial- portal gradient and hepatic Dioctanoy/glycerol, regulation of Feet, ulcers, wound healing, 1305 glucose uptake, 1659 cytosolic Ca?*, 621 Fetal insulin deficiency effects, 20 clearance, splanchnic, glucose cycling Diuresis, clonidine effects, 338 Fish-oil supplementation, effects on effects, 73 DNA fragmentation, streptozocin and impaired glucose tolerance, 583 cycling, postprandial hyperglycemia, alloxan effects, 1141 Free fatty acids 73 Dogs etomoxir effect on insulin action, 783 downregulation of protein kinase C, cholesterogenesis, 1630 hepatic glucose output regulation, 1274 conversion of oral glucose to lactate, 1033 glycogen catabolism, 263 738 kinetics, 1228 hepatic hypoglycemia Freund's adjuvant, complete, insulitis ethanol effects on output, 1319 autonomic nervous system role, prevention, 715 overproduction, New Zealand obese 1107 Fructosamine, screening criterion, 52 mice, 1480 hepatic glucoreceptors, 155 production regulated by pulsatile hemipancreatectomy, deterioration of insulin, 990 islet B-cell function, 1472 regulation by free fatty acids, 1033 islet amyloid polypeptide effect on uptake and arterial- portal gradient, insulin resistance, 999 G 1659 negative arterial- portal glucose G protein high, gene transcription, 102 gradient, 1659 effects on galanin, 1170 in vivo effects, 641 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 infusion, insulin release, 7, 15 diaminoguanidine, 1079 non-insulin- dependent diabetes inhibition of myo-inositol uptake, 1016 effect on mesangial cells, 549 mellitus level high-density lipoproteins, 377 endocrine pancreas, 166 effect on amylin secretion, 1005 tissue markers, 902 proinsulin, increased storage and familial diabetes, 1024 O-linked, 197 secretion, 985 signal peptide-length variation in Glycoxidation products, 405 postprandial apolipoprotein B gene, 1539 Growth glucose cycling effects, 73 metabolism decreased velocity, insulin- dependent MDL 73945 effects, 825 insulinlike growth factor |, 444 diabetes mellitus onset, 211 Hyperinsulinemia, Hispanic Americans, hormone, resistance to somatostatin, 509 regulation of, 395, 1467 oral 1251 Hypertension effect of diabetes, 1504 conversion to lactate, 738 load, 1659 insulin effect on prostaglandin synthesis, conversion to lactate, 738 production, 1223 tolerance Hypoglycemia age, 44 H B-adrenergic blockade effects, 1177 hemipancreatectomy, deterioration H,0., generation, streptozocin and autonomic nervous system role in of islet B-cell function, 1472 alloxan effects, 1141 glucagon secretion, 1107 impaired HbA,.,, screening criterion, 52 children, 358 familial diabetes, 1024 Heat shock protein 70, effect on hepatic glucoreceptors, 155 fish-oil supplementation, 583 pancreatic B-cells, 1418 insulin effects, 1057 Tanzanian study, 516 Heparin, effects on carbohydrate maternal, fetal skeletal malformations, transport metabolism, 686 1115 exercise training, 275, 401 Hepatocytes unawareness, 223 glyburide-stimulated, 1531 glycolysis activated by vanadate, 1355 B-adrenergic blockade effects, 1177 high-fat diet, 275 human, glycogen catabolism, 263 defective glucose counterregulation, transporter insulinlike growth factor binding 680 human skeletal muscle, 150 protein 1, 837 Hypoxemic glycogen synthesis, insulin-responsive gene, molecular Hispanic Americans, hyperinsulinemia, myocardial, 385 scanning, 1712 509 Hypoxic resistance, chronic measurement, 315 HIT a-adrenergic receptor blockade metformin, 850 cell lysis, 449 effect, 1652 molecular analysis. 413 T-15 islet cells, dioctanoylglycerol muscle/fat isoform, 472 effects, 621 with vanadate, L-type pyruvate kinase, HLA 462 association with insulin autoantibodies, Glucose-6- phosphate, in situ pathway 1146 metabolism, 1517 -DQaB heterodimer, 759 Glutathione metabolism, oxidative stress, -DQA1 allele, genetic susceptibility to incidence, insulin- dependent diabetes 344 insulin- dependent diabetes mellitus, Japanese, 319 Glyburide-stimulated glucose transport, mellitus, blacks, 748 Insulin 1531 -DQ £B-chain, high levels of islet cell action Glycemic control, hypoglycemia antibodies, 1435 free fatty acids, effect of etomoxir, unawareness, 680 -DQB1 allele, genetic susceptibility to 783 Glycerol! phosphate shuttle impairment, nsulin- dependent diabetes G protein, 521 227 mellitus human growth hormone effects, 141 Glycogen blacks, 748 prednisone effects, 141 synthase Finland, 1640 regulation of insulinlike growth factor mRNA, impaired expression in -DR®, no association of islet cell 1, 1525 skeletal muscle, 1740 antibody level, 1435 zinc effect, 612 myocardial, 385 -DR3 and -DR4 haplotypes, genetic analogues synthesis, amylin-induced insulin susceptibility, 478 human, insulin-receptor binding and resistance, 568 -DR4 haplotype, association with tyrosine kinase stimulation, 1488 Glycolysis, vanadate activation in insulin autoantibodies, 709 studies in rats, 628 hepatocytes, 1355 Human autoantibodies Glycolytic enzymes, mRNA levels, insulin fetal pancreas, endocrine-rich association with HLA, 709, 1146 release, 771 monolayers, 800 presence of nondiabetic individuals, Glycosaminoglycans, genetic defects, growth hormone, effect on insulin 1187 764 action, 141 stimulation of anti-insulin-receptor Glycosylation Hypercholesterolemia, 1630 antibody production, 966 advanced end products, receptor Hyperglycemia calcitriol stimulation, 1124 assay, 1731 effect on kinase activity of insulin deficiency, chronic undernutrition, autooxidative, 405 receptors, 633 1404 cataracts development, 1010 genetics, 82 degradation extracellular matrix changes, 1049 glucose level effect on amylin endosomes, 436 nonenzymatic secretion, 1005 HIT cell lysis, 449 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223-1363 February, 161—303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 deprivation, adipose tissue first- phase, New Zealand obese effect on muscle protein synthesis, metabolism, 666 mice, 1480 499 dietary phosphate restriction, 1134 stimulated amylin release decrease hormonal responses, 1057 downregulation of protein kinase C, precedes, 1615 insulin autoantibodies 1274 ionic channels of B-cells, 1069 HLA association, 1146 effect on linogliride effects, 878 levels, 709 aldose reductase expression, 1391 mRNA levels of glycolytic and islet cell antibody detection, 977 embryo growth and development, mitochondrial enzymes, 771 nephropathy 1574 postpancreatectomy, 181 glycosaminoglycan regulation, 764 muscle protein synthesis, 499 protein kinase C, age-dependent Jewish patients, 204 neuroaxonal dystrophy, 574 expression, 1496 von Willebrand factor as marker, 971 insulin receptors, 58 pulsatile, 349 neuropathy, bronchial response to prostaglandins and hypertension, regulation of hepatic glucose methacholine, 1100 1223 production, 990 platelet adhesion, 1410 fetal, deficiency effects, 20 sustained, from B-cell, 1453 prediction and prevention, 943 gene, 118 somatostatin-28 effects, 1163 remission phase, cyclosporine, 598 glycogan resistance retinopathy catabolism, 263 amylin-induced, 568 detection of inner retina dysfunction, 1122 synthase, 385 genetics, 28, 82 hormonal responses to hypoglycemia, high-fat diet, 280, 1297 Jewish patients, 204 1057 islet amyloid polypeptide, 305, 999 risk in vivo effects, 641 level of insulin receptor MRNA, 548 offspring, decreases with increasing level, familial diabetes, 1024 link to diacylglycerol and protein maternal age at pregnancy, 1 siblings, 831 mimetic, sodium seienate, 1675 kinase C, 1707 Insulinlike growth factor pancreatic, B-cell mass, 673 molecular analysis, 413 amino acid availability, 95 pork pancreas peptide as inhibitor, New Zealand obese mice, 1480 binding protein 1, 837 1210 protein tyrosine phosphatase, signal elevated level and increased receptor transduction, 939 retinopathy, 1725 abdominal skeletal muscles, 815 testosterone, 693 free, binding proteins, 959 binding tyrosine kinase, 295 glucose metabolism, 444 human insulin analogues, 1488 secretion, neuropeptide Y vs. protein synthesis in mesangial cells, signal amplification, 300 norepinephrine effects, 661 1346 gene stimulation of diacylglycerol and lipid release regulated by insulin, 1525 mutation detection, 777 synthesis, 1707 Insulinoma cells, 809 CDNA sequence, 249 storage, postpancreatectomy, 181 Interferon-y, 1382 kinase synthesis, postpancreatectomy, 181 Interleukin 18, B-cell function, 290 in vivo, 633 withdrawal, neurochemistry changes, Intracellular adhesion molecule 1, 1382 metformin effects, 850 217 IP3, effect on Ca?* transport, 323 phosphorylation, 66 Insulin-dependent diabetes mellitus Islet vanadyl effects, 492 animal model for analysis, 1375 cell antibodies molecular analysis, 413 apolipoprotein(a) level with association with HLA-DQB and mRNA microalbuminuria, 787 HLA-DR, 1435 effects of media conditions, 58 CD5* B lymphocytes, 1314 autoimmune thyroid disease, 319 insulin resistance, 548 children CD5* B lymphocytes, 1314 naturally occurring variants, m decreased growth velocity, 211 detection/progression to O-linked glycosylation, 197 hypoglycemia, 358 insulin- dependent diabetes regulation, lymphocytes, 364 cognitive functions, 952 mellitus, 977, 1128 substrate, phosphorylation, 66 diagnosis, T lymphocyte reactivity, B-cells stimulation of anti-idiotypic antibody 1128 adhesion molecules, 1382 production, 966 familial, autonomic nervous system deterioration after tyrosine kinase, 295, 521 dysfunction, 1611 hemipancreatectomy, 1472 resistance, prevention by protein genetic susceptibility to cytodifferentiation, 1041 kinase C, 1440 blacks, 748 dysfunction, hyperglycemia, 166 skeletal muscle, 1691 Finland, 1640 macrophage influx, 1459 regulation of glycosylated HLA-DR3 and -DR4 haplotypes, 478 pancreatic phosphatidylinositol, 1297 glomerular filtration rate, aldose coenzyme A, 327 release reductase inhibition, 527 glycerol phosphate shuttle alginate- polylysine- alginate growth hormone resistance to impairment, 227 microencapsulation, 37 somatostatin, 1251 streptozocin and alloxan effects on exercise training, 401 hypoglycemia H20. generation and DNA G protein, 1 a-adrenergic blockade effects, 1177 fragmentation, 1141 glucose infusion, 7, 15 unawareness, 223, 680 secretory granules, Ca?*-dependent hemipancreatectomy, deterioration incidence, Japanese, 319 phosphorylation, 1063 of islet B-cell function, 1472 insulin transplantation impaired deprivation, 666 anti-CD4 immunotherapy, 1430 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405—520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 cyclosporine effects, 931 Lipoproteins, high-density T lymphocytes fetal pig to mice, 858 cholesterogenesis, 1630 altered, 429 graft standardization, 908 nonenzymatic glycosylation, 377 Ves OF Ves expression not prolongation of survival, 482, 1511 Liver required, 1555 purification, 921 insulinlike growth factor | regulated, Ve11 and insulitis, 1580 rejection, 754 1525 xenograft survival prolonged, 1511 streptozocin-induced diabetes, 1157 membranes, nonenzymatic obesity genes, 1360 xenografts, antilymphocyte sera, 482 glycosylation marker, 902 transplantation of fetal pig proislets, Islet amyloid polypeptide diabetes effects on phosphotyrosine 858 Ca**-calcitonin gene-related peptide and phosphoserine phosphatase, See also Streptozocin-induced effects, 948 1620 diabetes molecular analysis, 413 regulation of glucose metabolism, Microalbuminuria, apolipoprotein(a) insulin release, 310, 1701 1467 level, 787 insulin resistance, 305, 999 Lymphocyte Micronesian Nauruans, insulin gene, 118 See also Amylin CD5* B, insulin-dependent diabetes Mitochondrial enzymes, mRNA levels, Islets of Langerhans mellitus, 1314 insulin release, 771 GABA, 1365 function- associated antigen 3, 1382 Monoaminoguanidine, 1079 glucagonlike peptide |, 1292 regulation of insulin receptors, 364 Mononuclear cells, HIT cell lysis, 449 transplantation, xenograft survival Muscle prolonged, 1511 denervated, insulin stimulation of diacylglycerol and lipid synthesis, 1707 /fat glucose transporter, 472 Macrophage glucose transporter J advanced glycosylation end products, exercise training, 275 Japanese, insulin- dependent diabetes receptor assay, 1731 high-fat diet, 275 mellitus influx preceding insulitis, 1459 protein synthesis, effect of insulin and genetic susceptibility, 759 involvement in B-cell destruction, 1586 amino acids, 499 incidence, 319 Macrovascular disease, platelet skeletal Jewish patients, risk factors for adhesion, 1410 abdominal, insulin receptors, 815 nephropathy and retinopathy, 204 Maillard reaction, 405 fatty acid supplementation, 532 Major histocompatibility complex class II, glycogen synthase mRNA, impaired expression on CD45* cells, 648 expression, 1740 Maternal diabetes, retarded human, glucose transporters, 150 preimplantation, 457 insulin-receptor kinase, 169% K MDL 73945, 825 protein tyrosine phosphatase, 939 Mesangial myo-inositol Kidney cells cytosolic protein kinase C activity membranes, nonenzymatic insulinlike growth factor effects, 1346 corrected, 1545 glycosylation marker, 902 nonenzymatic glycosylation effects, depletion hypothesis, 1335 regulation of glucose metabolism, 540 effect on 1467 expansion, aminoguanidine effects, embryo growth and development, 1328 1574 Metformin, glucose transporters, 850 glomerular filtration rate, 465 Methacholine, bronchial response, 1100 Na*-K*-ATPase activity, 558 Mexican Americans, apolipoprotein E, neuroaxonal dystrophy, 574 L 334 Na*-K*-ATPase transport activity, 240 Lactate, converted from oral glucose, Mg?*, effect on Ca?* transport, 323 uptake 738 Mice inhibition of by glucose, 1016 Lambs, fetal insulin deficiency effects, 20 B-cell destruction, macrophage Na*-K*-ATPase activity, 726 Late-onset, elevated insulinlike growth involvement, 1586 Myopathy, fatty acid supplementation, factor | and retinopathy, 1725 genetics, insulin resistance and 532 Leprechaunism, 28 hyperglycemia, 82 Leukocytes, interaction with endothelium, New Zealand obese, insulin 1267 resistance, 1480 Linogliride NOD effect on ATP-sensitive K* channel altered T lymphocytes, 429 activity, 885 B-cell destruction by T lymphocytes, effect on pancreatic hormone release, 1203, 1210 Na*-K*-ATPase activity complete Freund's adjuvant, 715 effect of Lipids congenital malformations, 1245 chronic a-adrenergic receptor effects on carbohydrate metabolism, major histocompatibility complex blockade, 1652 686 Class II expression, 648 diabetes, 1560 synthesis, stimulation by insulin, 1707 NIT-1, 842 myo-inositol Lipofuscin products, effect of reduced regulation of glucose metabolism, effects, 558 vitamin E, 1241 1467 uptake, 726 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405—520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305—404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 ouabain-sensitive, diabetes and glycogen synthase mRNA, impaired Pancreatectomy, insulin action, 181 glucagon effects, 1603 expression in skeletal muscle, Phorbol esters, downregulation of protein prostaglandin E, analogue effect, 726 1740 kinase C, 1274 transport, myo-inositol, 240 Hispanic Americans, hyperinsulinemia, Phosphatidylinositol N-acetylheparosan deacetylase, 509 glycosylated, regulation of by insulin, diabetes-induced inhibition, 1449 hyperglycemia, endocrine pancreas, 1297 Natriuresis 166 hydrolysis, 1282 clonidine effects, 338 insulin Phospholipids nephropathy, 893 gene, 118 erythrocyte, decreased incorporation Nephropathy level, familial diabetes, 1024 of long-chain fatty acids, 1645 atrial natriuretic peptide, 893 receptor gene, 249 hydrolysis, 1565 glycosaminoglycans, genetic defects, mutations, 777 Phosphorylation 764 islet amyloid polypeptide, 305, 310 intermolecular, insulin receptors, 300 Jewish patients, 204 Mexican Americans, apolipoprotein E, islet secretory granules, 1063 N-acetylheparosan deacetylase 334 Phosphoserine phosphatase, diabetes inhibition, 1449 New Zealand obese mice as animal effects, 1620 nonenzymatic glycosylation effects, model, 1480 Phosphotyrosine phosphatase, diabetes 540 nonobese, insulin receptors, effects, 1620 postglomerular microvessels, 791 abdominal skeletal muscles, 815 Pima Indians, ins‘ilin gene, 118 von Willebrand factor as marker, 971 prevalence, Paleo-Indians, 161 Platelets Nerve proinsulin, increased storage and adhesion, 1410 peripaehf-efraeadctlr, e nc1eo6rn5gd2iu cct iroenc,e ptcohrr onbilco ckade proteistner carntesytdriuoocsnti,in oen 9,8p 5h 9o3s9p hatase, signal aggreegfaftecitosn,, 23vi3t amin E and PP-56 sciati8c7, 3 oxygen free radical effects, rissk exf achtoorrsm one—binding globulin level, PPoollyyocly stic ovarian syndrome, 693 Neuroaxonal dystrophy, therapy effects, 123 chroni1c6 52a -adrenergic receptor effect, 74 whites, 796 Neuroblastoma cells, myo-inositol tyrosine kinase, 295 pathway inhibition, effects on supplementation, 240 NIT-1, 842 glomerular filtration rate, 465 Neuroendocrine abnormalities, Nonenzymatic browning, cataracts Ponalrestat, peripheral neuropathy, 129 neuropeptide Y concentrations, 1423 development, 1010 Postglomerular microvessels, 791 Neuropathy Norepinephrine vs. neuropeptide Y, Prednisone, effect on insulin action, 141 autonomic effects on insulin secretion, 661 Pregnancy bronchial response to methacholine, Nutrition, somatomedin, 95 hypoglycemia, fetal skeletal 1100 malformations, 1115 skin potential response, 867 increasing maternai age decreases axonal transport, 111 risk in offspring, 1 endoneurial microvessels, 1090 Prevalence, non-insulin- dependent fatty acid supplementation, 532 Oo diabetes mellitus neuroaxona! dystrophy, therapy Obesity Micronesian Nauruans, 118 peripehfefreaclt,s , p5on7a4l restat, 129 genes, 1360 PPailmeao -IInnddiiaannss,, 111681 neuropepide Y concentrations, 1423 myo-inositol supplementation, 240 Oligosaccharides, O- and N-linked, 197 Proinsulin, increased storage and Neuropeptide Y Oral glucose tolerance test, Tanzanian secretion, 985 concentrations and study, 516 Propranolol effects on neuroglycopenic obesity/neuroendocrine OQuabain-sensitive Na*-K*-ATPase, symptoms, 1177 abnormalities, 1423 Prostaglandin diabetes and glucagon effects, 1603 vs. norepinephrine, effects on insulin Oxygen free radical, effects on sciatic E, analogue, effect on Na*-K*-ATPase secretion, 661 nerve, 873 activity, 726 Non-insulin- dependent diabetes mellitus insulin effect on production of, and apolipoprotein B gene, 1539 hypertension, 1223 B-cell desensitization to glucose, 486 Protease, B-cell function, 290 decrease of stimulated amylin release, Protein 1615 P G epinephrine effects on a- and B-cells, insulin release, 1 1194 Paleo-Indians, “thrifty” genotype, 161 insulin action, 521 familial diabetes, 1024 Pancreas G,, impaired coupling to adipocytes, glucose acini, phosphatidylinosito!l hydrolysis, 88 cycling, 73 1282 kinase C level, familial diabetes, 1024 hemipancreatectomy, islet B-cell age-dependent expression, 1496 production, effect of ethanol, 1319 function deterioration, 1472 diacylglycerol and glucose transporters human fetal, endocrine-rich transport, 1707 insulin-responsive gene, molecular monolayers, 800 downregulation, 1274 scanning, 1712 pork, insulin inhibitor, 1218 glyburide-stimulated glucose muscle/fat isorform, 472 transplantation, 1085 transport, 1531 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223-1363 February, 161—303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 myo-inositol correction of cytosclic pancreatic acini, phosphatidylinositol retinopathy protein kinase C activity, 1545 hydrolysis, 1282 elevated insulinlike growth factor | prevention of insulin-receptor proinsulin, increased storage and levels, 1725 tyrosine kinase resistance, 1440 secretion, 985 Jewish patients, 204 synthesis, insulinlike growth factor protein kinase C expression, 1496 effects, 1356 regulation of liver glucose tyrosine phosphatase, skeletal muscle, metabolism, 395 939 skeleial muscle insulin-receptor Proteoglycan kinase, 1691 Ss production, ascorbic acid, 371 vanadyl effects, 492 Screening, 1,5-anhydroglucitol levels, 52 synthesis, insulinlike growth factor vitamin E reduction, effect on Serotonin turnover, insulin withdrawal, effects, 1356 lipofuscin products, 1241 217 Wistar Sex hormone—binding globulin level, risk diabetes and hypertension, 1504 factor for non-insulin- dependent dietary phosphate restriction, 1134 diabetes mellitus, 123 exercise and insulin release, 401 Signal peptide—length variation in R glucagonlike peptide-|, 1292 apolipoprotein B gene, 1539 Rats gluconeogenesis inhibition, 1259 Skin potential response, 867 ACI, transplantation tolerance, 1430 glucose effects in vivo, 641 Sodium selenate, insulinlike effects, 1675 BB glutathione metabolism, 344 Somatomedin, 95, 1525 8-cell-specific antigenic changes, insulin Somatostatin 269 effects in vivo, 641 -28, effect on insulin secretion, 1163 RT6-depleted, T-lymphocyte release, 37 inhibition by GABA, 1365 requirement, 423 resistance, dietary fats, 280, 1397 resistance of growth hormone BBW, diabetes and hypertension, secretion, neuropeptide secretion, 1251 1504 Y/norepinephrine effects, 661 Sorbinil BB/Wistar, axonal transport, 111 leukocyte- endothelial interaction, effects on neuroaxonal dystrophy, 574 BB/Wor 1267 retinal pigment epithelial cells, 1335 environmental viruses, 259 linogliride effect on ATP-sensitive K* Sorbitol insulin and statil effects on aldose channels, 885 accumulation and aldose reductase reductase expression, 1391 maternal hypoglycemia and fetal activity, 1233 viral infection, 255 skeletal malformations, 1115 retinal pigment epithelial cells, 1335 GK, B-cell desensitization to glucose, muscle, exercise training, 275 Spectrin, oxidation, 701 486 somatostatin-28 effects on insulin Spermine, effect on Ca?* transport, 323 insulin secretion, 1163 Statil, effect on aldose reductase analogue studies, 628 vanadate, L-type pyruvate kinase, expression, 1391 release, glucose infusion, 7, 15 462 Streptozocin Lewis, transplantation tolerance, 1430 xenograft survival prolonged, 1511 effects on H2O2 generation and DNA Long-Evans Wistar-Furth, islet xenograft survival, fragmentation, 1141 a-calcitonin gene-related peptide 482 receptor regulation of diabetic effects, 948 Wistar-King, glucose level! effect on bladder, 1150 insulin- dependent diabetes mellitus amylin secretion, 1005 Streptozocin-induced diabetes without lymphopenia, 1375 Zucker, obese, neuropeptide Y baboons Sprague-Dawley concentrations, 1423 B-cell mass and insulin content, 673 amylin-induced insulin resistance, See also Streptozocin-induced pulsatile insulin delivery, 349 568 diabetes dogs, cholesterogenesis, 1630 bladder regulation, 1150 Renal function, postglomerular mice glomerular filtration rate, 465 microvessels, 791 antigenic change in B-cell, 1157 glycogen synthase, 385 Retinal pigment epithelial ceils, 1335 macrophage influx preceding hepatocytes, phosphorylation, 66 Retinopathy insulitis, 1459 insulin detection of inner retina dysfunction, maternal diabetes, 457 degradation, 436 1122 tryptophan effects on depression stimulation of diacylglycerol and elevated insulinlike growth factor | and aggression, 1598 lipid synthesis, 1707 levels, 1725 rats insulinlike growth factor, 444, 959 Jewish patients, 204 aminoguanidine effects, 1328 islet Risk factors axonal transport, 111 amyloid polypeptide, 1701 insulin- dependent diabetes mellitus bladder regulation, 1150 cytodifferentiation, 1041 offspring, decreases with increasing chronic undernutrition, 1404 linogliride effect on hormone release, maternal age at pregnancy, clonidine effects, 338 878 1679 chronic a-adrenergic receptor matrix gene expression, 605 nephropathy, Jewish patients, 204 blockade effects, 1652 metformin effects on glucose non-insulin- dependent diabetes 1,2-diacylglycerol content in transport, 850 mellitus thoracic aorta, 820 oxygen free radical effects on sciatic sex hormone- binding globulin level, diabetes effect on Ca?* and nerve, 873 123 Na*-K*-ATPase, 1560 pancreatectomy, insulin action, 181 whites, 796 embryo growth and development, DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746 SUBJECT INDEX 1991 insulin and myo-inositol effects, T U 1574 Ulcers, feet, wound healing, 1305 T lymphocytes fatty acids decreased incorporation into autoantibody changes, 590 erythrocyte phospholipids, B-cell destruction, 1203, 1210 1645 changes preceding onset, 429 diet supplementation, 532 diagnosis of insulin- dependent Vv glucagon neutralization effect on diabetes mellitus, 1128 Vanadate impaired receptor coupling, 88 requirement for in RT6-depleted rats, activation of glycolysis in hepatocytes, in situ pathway metabolism, 1517 423 1355 insulin withdrawal, 217 Ves OF Ves expression not required for with glucose, L-type pyruvate kinase, islet transplant, endocrine function diabetes, 1555 462 deterioration, 134 Va11 and insulitis, 1580 Vanadyl, effects on carbohydrate and islets, glycerol phosphate shuttle Tanzania, oral giucose tolerance test, lipid metabolism, 492 impairment, 227 516 Vascular supply, chronic a-adrenergic myo-inositol Testosterone, insulin resistance, 693 receptor blockade effect, 1652 correction of cytosolic protein Third-party thyroid allografts, Viral infection, rats kinase C activity, 1545 transplantation rejection, 754 altered diabetes expression, 255 Na*-K*-ATPase activity, 558 Tissue fluorescence, aminoguanidine environment, 259 N-acetylheparosan deacetylase effects, 1328 Vitamin E inhibition, 1449 Tolbutamide, effect on pancreatic effects on platelet aggregation, 233 neuroaxonal dystrophy therapy hormone release, 878 reduced, effect on lipofuscin products, effects, 574 Transcutaneous oxygen tension, 1305 1241 ouabain-sensitive Na*-K*-ATPase, Transplantation von Willebrand factor, nephropathy diabetes and glucagon effects, islet development, 971 1603 anti-CD4 immunotherapy, 1430 prostaglandin E, analogue effects, 726 cyclosporin effects, 931 graft standardization, 908 sodium selenate insulinlike effects, 1675 purification, 921 Ww rejection, 754, 1719 1,2,6-trisphosphate effects, 233 ‘Whites prolongation of survival, 482, 1511 vanadate activation of glycolysis in genetic susceptibility to hepatocytes, 1355 pancreas, 1085 insulin- dependent diabetes vanadyl effects, 492 rat islet, endocrine function mellitus, 759 deterioration, 134 vitamin E effects, 233 non-insulin- dependent diabetes Stress, oxidative 1,2,6-trisphosphate, effect on platelet mellitus, risk factors, 796 complications development, 405 aggregation, 233 Wound healing, 1305 glutathione metabolism, 344 Tumor necrosis factor a, 1382 Sulfonylurea agents and glucose Tyrosine kinase, 295 transport, 1531 insulin receptors, 521 Sulfotransferases and obesity genes to resistance, prevention by protein mediate diabetes, 1360 kinase C, 1440 z Sympathetic cholinergic function, stimulation, human insulin analogues, Zinc validation of test for, 867 1488 effect on biguanide antihyperglycemic Synthesized peptide, measurement of Tryptophan effects on depression and drugs, 612 glucose transporter, 315 aggression, 1598 effect on insulin action, 612 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405—520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305—404 June, 653-790 September, 1085-1222 December, 1565-1746 Author index A Begovic, M.E., 825 Burcharth, F., 764 Begum, N., 575 Buse, J.B., 181 Abbate, S.L., 111 Bell, G.I., 305, 413 Buse, M.G., 311 Abplanalp, W.A., 1251 Bell-Farrow, A., 902 Butler, L., 259 Adams, H.B., 315 Bellush, L.L., 217 Butler, P.C., 73 Aebischer, P., 482 Bendtzen, K., 290 Agranoff, B.W., 1545 Benecke, H., 850 Ahrén, B., 660 Bengtsson, C., 123 Ahroni, J.H., 1305 Bennet, W.M., 499 Akanuma, Y., 52 Akashi, M., 31 Bennett, T., 948 Cc Berghmans, M., 908 Akazawa, M., 31 Bergman, R.N., 155, 738 Cagliero, E., 102, 653 Akazawa, S., 319, 31 Akerblom, H.K., 115 Berman, N., 1453 Cama, A., 118 Berrie, M.A., 990 Cameron, N.E., 532, 211 Albert, E., 1146 Bersch, N., 28 Cammarata, P.R., 731 Alberti, K.G.M.M., 516 Bertherat, J., 1100 Camipbell, |.L., 1128 Alberts, A.W., 493 Bertrand, G.R., 660 Cantor, A.B., 1314 Alcalde, L., 1382 Best, J.D., 787, 867 Caprio, S., 358 Allen, C., 831 Biegel, A.A., 1187 Caputo, S., 1122 Allon, M., 1134 Bierman, E.L., 377 Carel, J.-C., 809 Alper, C., 478, 709 Bjorbeek, C., 522 Caro, J.F., 150, 472 Alters, S., 1430 Andersen, P.H., 522 Bjorn, S., 1488 Carter, W.J., 36 Bjorntorp, P., 123, 783 Carter-Su, C., 472 Anderson, J.H., 1187 Blackard, W.G., 1033 Castano, L., 709 Andreani, D., 1685 Block, N.E., 311 Castell, J.V., 263 Andres, R., 44 Boden, G., 686 Cebon, J.S., 1128 Arner, P., 666 Boehm, B.O., 1435 Cefalu, W.T., 902 Arnold, T., 1274 Boerwinkle, E., 334, 1539 Chaffin, D.G., 20 Asano, T., 315 Bogardus, C., 939 Chakrabarti, S., 1391 Asawa, T., 1141 Atkins, J.L., 791 Bolinder, J., 666 Chan, L., 1539 Atkinson, M.B., 111 Boner, G., 204 Chandrasekar, B., 1282 Bonifacio, E., 977 Chanson, M., 1069 Avidan, A., 492 Bonner-Weir, S., 673 Chapman, H.D., 1360 Awaji, Y., 820 Awdeh, Z.L., 709 Bosch, F., 1355 Charles, M.A., 796 Bosco, D., 1069 Chen, K.S., 315 Axelrod, L., 1223 Bose, C., 948 Chen, S.-H., 1539 Bosi, E., 977 Chen, Y.-D.1., 295 Bottazzo, G.F., 977 Cheong, E., 878 Boulware, S.D., 358 Cherrington, A.D., 412 Bourey, R.E., 401 Chi, C.-W., 1218 Baba, S., 52, 1203, 1210 Bowsher, R.R., 1453 Chick, W.L., 809 Baek, H.-S., 131 Boyko, E.J., 509, 1305 Chikuba, N., 319 Bailbé, D., 227, 486 Boyle, P.J., 1177 Chisholm, D.J., 275, 280, 1397 Bak, J.F., 522 Brelje, T.C., 1365 Choi, $.B., 568 Banduch, D., 568 Brendel, M.D., 858 Choi, W.-H., 777, 181 Banga, J.D., 1410 Brennan, M.C., 1335 Chou, H.-F., 1453 Bansal, V., 1079 Bretzel, G.R., 858 Christiansen, J.S., 527 Baquer, N.Z., 1467 Breuer, A.C., 111 Chuwa, L., 516 Barbetti, F., 118 Bril, V., 1090 Ciavatti, M., 233 Barnett, A.H., 129, 748 Brink, S.J., 709 Clark, P.W., 275, 1397 Barrett, D.J., 1314 Brown, D.M., 1346 Clark, R.M., 20 Barrett, E.J., 385 Brown, F.M., 194 Clarke, B., 1328 Bartrons, R., 462 Brownlee, M., 540 Clarke, W.L., 680 Battell, M.L., 195 Bryer-Ash, M., 633 Clementi, A., 1685 Baynes, J.W., 190, 405, 1010 Buchanan, C., 472 Clore, J.N., 1033 Becker, F., 977 Buffington, C.K., 693 Cochrane, C., 82 Bedoya, F.J., 7, 15 Bugawan, T.L., 478 Cohen, R.M., 1251 Beebe, L.F.S., 457 Bunag, R.D., 150 Colca, J.R., 1669 DIABETES: VOLUME 40 (1991) PAGE NUMBERS BY ISSUE January, 1-159 April, 405-520 July, 791-942 October, 1223-1363 February, 161-303 May, 521-651 August, 943-1084 November, 1365-1564 March, 305-404 June, 653-790 September, 1085-1222 December, 1565-1746